PHASE II STUDY TO EVALUATE THE COMBINATION OF RITUXIMAB AND DEPOCYTE® IN THE C5R CHEMOTHERAPY PROTOCOL IN PATIENTS BETWEEN THE AGES OF 18 AND 60 YEARS WITH PRIMARY CEREBRAL NON-HODGKIN LYMPHOMA AND SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA WITH NEUROMENINGEAL INVASION AT DIAGNOSIS: